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1. Introduction 
The pharmacological and immunological character- 
istics of the nicotinic acetylcholine receptor (AChR) 
in its membrane as well as in its aqueous and detergent 
solubilized forms have been studied in details [l-4]. 
All these receptor preparations express similar binding 
properties to cholinergic ligands and they can all 
induce experimental autoimmune myasthenia gravis 
(EAMG) [5-71. 
Molecular modifications of proteins are a useful 
approach for elucidating the relationship between 
their structure and biological function. We have 
studied the effect of denaturation and of proteolytic 
degradation of AChR on its biological activity. Such 
studies demonstrated that a denatured AChR prepara- 
tion obtained by reduction and carboxymethylation 
of AChR in 6 M guanidine (RCM-AChR) is devoid of 
both abilities to bind choline@ ligands and to induce 
EAMG [8], but had a suppressive ffect on EAMG 
[9]. On the other hand tryptic digestion of AChR did 
not change the pharmacological specificity and 
pathological myasthenic activity of the receptor 
molecule although it resulted in a simpler and smaller 
molecule composed of one type of subunit (M, 
-27 000), lower in molecular weight from all the 
four subunits present in the intact receptor [lo]. 
Polyalanylation of proteins is a specific mild 
chemical modification achieved by attaching poly@,L- 
Ala) side chains to free amino groups on proteins, by 
polymerization of ZV-carboxy-D,L-alanine anhydride 
in aqueous media. The reason for using D,L-Ala 
anhydride for polymerization is that poly(D,L-Ala) is 
water soluble whereas either poly(L-Ala) or poly(D- 
Ala) are not soluble [ 111. Polyalanylation of enzymes 
did not change their enzymic activity [ 121; also in 
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some cases the attachment of D,L-Ala peptide chains 
to proteins has increased their solubility [ 131. 
We report here on the preparation and characteriza- 
tion of poly(D,L-Ala) AChR (PA-AChR). Alanylation 
of AChR did not affect significantly the cholinergic 
binding properties of the receptor whereas it abolished 
its myasthenic activity. Thus, by this modification 
the pharmacologic and myasthenic activities of the 
receptor have been dissociated. 
2. Materials and methods 
AChR was isolated from the electric organ of 
Torpedo culifomica and was purified as in [6]. Radio- 
labelling of proteins with “‘1 was performed by the 
chloramine-T method [ 141. Specific binding of 
cu.bungarotoxin (ol-Bgt) to AChR and to PA-AChR 
was determined by measuring the amount of 12sIa- 
BgT which coprecipitates with the receptor in 35% 
saturated ammonium sulfate [6]. 
2.1. Preparation of PA-AChR 
PA-AChR was prepared by reacting AChR with 
N-carboxy-D,L-alanine anhydride [ 151 in a procedure 
similar to that described for alanylation of other 
proteins [ 11,131. AChR (1 mg/ml phosphate buffered 
saline (PBS)) was reacted in the cold with Ncarboxy- 
D,L-alanine anhydride dissolved in anhydrous dioxane 
(4 mg anhydridelmg protein; final cont. dioxane was 
sZ;lO%). The mixture was kept for 24 h at 4°C with 
gentle stirring and was then dialyzed for 3 days against 
several changes of PBS. The dialysate was centrifuged 
to remove any highly aggregated material. For control, 
AChR alone or AChR in 10% dioxane were treated in 
a similar manner. 
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2.2. Biochemical analysis 
Amino acid composition was determined in a 
Beckman automatic amino acid analyzer, Model 12 1. 
Sedimentation coefficients were determined by 
sucrose gradient centrifugation and by analytical 
ultracentrifugation [6]. Inhibition constants for 
cholinergic ligands were determined by measuring 
their effect on the initial rate of formation of the 
complex between ‘2sI+Bgt and the tested receptor 
preparation, by a procedure similar to that in 
[6,16,17]. 
2.3. Immunization and immunological assays 
Rabbits were immunized 2 or 3 times, each time 
with 100 I.cg PA-AChR (in 1 ml) emulsified with equal 
volumes of complete Freund’s adjuvant. Injections 
were given into the footpads and intradermally at 
multiple sites at 30 day intervals. For comparison, 
other rabbits were injected once or at most twice 
with AChR. Antisera were analysed by immuno- 
diffusion and radioimmunoassay. Binding and inhibi- 
tion experiments were performed by radioimmuno- 
assay procedures similar to those in [ 181. 
3. Results 
3.1. Biochemical characterization of PA-AChR 
Amino acid analysis of PA-AChR demonstrates 
that an av. 5 Ala residues were attached/l Lys 
residue in the receptor molecule. This corresponds to 
a weight increase of -18% based on a content of 
6 mol % lysines in AChR [6]. In order to verify that 
the alanine residues were covalently bound to AChR 
we tested whether PA-AChR can be adsorbed to an 
antibody column of anti-polyalanine antibodies. 
Radioiodinated PA-AChR was adsorbed to a Sepharose 
adsorbent of anti-poly(D,L-Ala)-ribonuclease immuno- 
globulins, whereas 12’I-AChR was not adsorbed at all. 
Table 1 
I,, values for AChR and PA-AChR 
I,, 00 
Ligand AChR PA-AChR 
d-Tubocurarine 9.0 x 1o-7 5.0 x 10-a 
Carbamylcholine 3.0 x 1o-s 2.9 x 1o-4 
Lu-Bungarotoxin 2.0 x IO-‘0 3.2 X 1O-9 
Atropine 2.2 x 1o-4 1.0 x 1o-3 
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Fig.1. Immunodiffusion of anti-AChR serum (well 7) with 
PA-AChR (wells 1,5), polyalanyl BSA (well 2), AChR (wells 
3,6) and AChR treated with 10% dioxane (well 4). 
The adsorbed PA-AChR could be eluted from the 
adsorbent by means of poly(D,L-Ala) bovine serum 
albumin (4 mg/ml). This experiment proves that the 
added Ala residues were covalently attached to AChR. 
Sucrose density gradient centrifugation of 
PA-AChR (complexed with ‘2sIa-Bgt), demonstrated 
a sedimentation coefficient of 9 S. On analytical 
ultracentrifugation PA-AChR revealed one component 
of 9.3 S whereas with the unmodified receptor two 
protein components of 9 S and 13.4 S were observed, 
as in [6]. 
Alanylation of AChR did not affect significantly 
the capacity to bind cll-Bgt . AChR and PA-AChR 
bound, respectively, 8000 and 6600 pmol cu-Bgt/mg 
receptor. The control preparation of AChR which 
was reacted with 10% dioxane in the absence of the 
anhydride had also a slightly decreased specific activity 
(6700 pmol ar-Bgt/mg). When the pharmacologic 
specificities of PA-AChR and AChR were compared 
by measuring the inhibition of the binding of 12’Ia- 
Bgt to PA-AChR and AChR by several cholinergic 
ligands, slightly higher Iso values (5-lo-times higher) 
were obtained for the modified receptor than those 
obtained for AChR (table 1). 
3 -2. Immunological characterization of PA-AChR 
The immunogenicity and antigenicity of PA-AChR 
were tested and compared with those of AChR. The 
binding of PA-AChR to anti-AChR serum is identical 
to the binding of AChR to this antiserum. This was 
observed by immunodiffusion (fig.1) and radio- 
immunoassay experiments. Similar binding of 12’1- 
AChR and 12’1-PA-AChR to anti-AChR serum was 
observed (fig.2a). Moreover, unlabelled AChR and 
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Fig.2. Binding of ‘ZSI-AChR (o), “‘1-PA-AChR (0) and of 
1251-RCM-AChR (A) to anti-AChR serum (A) and to anti- 
PA-AChR serum (B). 
PA-AChR inhibit to a similar extent the binding 
reactions of 125 I-AChR and 12’ I-PA-AChR to anti- 
AChR serum (fig.3a,b). 
As an immunogen PA-AChR appears to be quite 
different from AChR. Most of the antibodies in PA- 
AChR injected rabbits are directed against the poly- 
alanine side chains (fIg.2b,3c). There is only a partial 
cross reactivity between anti-PA-AChR serum and 
AChR. It should be noted also that the binding of anti- 
PA-AChR antibodies to a denatured receptor prepara- 
tion (reduced carboxymethylated AChR, RCM-AChR 
[8]) is better than their binding to AChR (fig2b). 
Antibodies to AChR were shown to block the 
physiological activity of AChR [5,19,20] and to 
inhibit the binding of cuBgt to the receptor [6]. 
However, anti-PA-AChR antibodies do not inhibit the 
binding of a-Bgt to AChR. This is in agreement with 
the finding that these antibodies bind poorly to 
AChR and that this reactivity is probably via non- 
structural antigenic determinants present on the 
03 3 Jo 3co3Omo3 3 30 3003cmo3 3 30xX)3030 
Mibltodng) 
Fig.3. Inhibition of the binding of: (A) “‘1-AChR to anti- 
AChR-serum; (B) lZSI-PA-AChR to anti-AChR serum; (C) 
“‘1PA-AChR to anti-PA-AChR serum by AChR (-_), 
PA-AChR (--) and PA-BSA (polyalanyl-BSA) (-.-). 
denatured receptor (RCM-AChR). Anti-RCM-AChR 
antibodies also do not block the binding of cu-Bgt o 
AChR as reported [8]. 
Repeated immunizations of rabbits with PA-AChR 
did not result in any clinical symptoms of experimental 
autoimmune myasthenia gravis (EAMG). However, 
3 preimmunizations with PA-AChR before administra- 
tion of AChR had an effect on the onset of EAMG, 
indicating the immunological relationship between 
the two receptor derivatives. In 5 out of 10 rabbits, 
preimmunization with PA-AChR resulted in a 
protecting effect expressed by a delay in the onset or 
prevention of EAMG, whereas in another 3 there 
seemed to be a facilitating effect and EAMG appeared 
5-10 days following the first AChR administration. 
4. Discussion 
Chemical modification of AChR provides a valuable 
tool for identifying and analysing the structure of the 
biologically active site(s) of the molecule. These 
studies demonstrate that the myasthenic activity of 
the receptor is not necessarily identical to its pharma- 
cological activity. PA-AChR which retains the 
cholinergic binding activity of AChR does not induce 
myasthenia. In two other AChR derivatives studied in 
our laboratory both functions were expressed similarly. 
Denatured AChR (RCM-AChR) was shown to be 
devoid of both cholinergic and myasthenic activities 
[8,9] whereas in trypsinated AChR (T-AChR) both 
functions were not affected [lo]. 
The finding that polyalanylation of lysines does 
not interfere with the binding properties of AChR 
may imply either that lysine residues (or other free 
amino groups) do not participate in the cholinergic 
binding site or alternatively that these particular resi- 
dues in the active site were not susceptible to the 
modification. 
The immunogenicity of PA-AChR is markedly 
different from that of AChR. The polyalanine side 
chains appear to be immunopotent and the majority 
of the antibodies in anti-PA-AChR is directed against 
the polyalanine side chains (fig.3c). However, there 
are also some anti-AChR antibodies; these latter anti- 
bodies are probably directed against non structural 
determinants of AChR, which are not effected by 
denaturation, as they react preferably with RCM-AChR 
(fig.2). This specificity [9] is also compatible with 
the finding that PA-AChR is not myasthenic. 
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Analysis of the pharmacologic, antigenic and 
immunogenic specificities of PA-AChR contribute 
towards the elucidation of the structure of the 
biological active sites of AChR. The non-pathogenicity 
of PA-AChR along with its antigenic specificity 
renders it also a possible candidate for regulating 
EAMG. 
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